news aktuell GmbH

R-Biopharm AG: Flu tests from R-Biopharm also detect new virus variants

Share
Detect reliably the current flu virus variants: The RIDA®GENE flu assays from R-Biopharm
Picture: Getty Images
Detect reliably the current flu virus variants: The RIDA®GENE flu assays from R-Biopharm Picture: Getty Images

Darmstadt, November 25, 2022: The flu season has begun and different virus variants are also circulating in Germany. With the flu tests from biotechnology company R-Biopharm, patients quickly have certainty: Its RIDA®GENE Flu assays also reliably detect the two novel variants. The company made the announcement with regard to influenza A H1N1pdm09, which is circulating primarily in the United Kingdom, and the H3N2 subtype, which was rampant in Denmark in the spring and is currently dominating influenza activity in Germany.

 "Mutations in the target gene (MP gene) can affect the diagnostic performance of influenza screening assays, producing false-negative test results," explains Dr. Andreas Simons, Head of Product Management at R-Biopharm. " Alignments of the detection systems we used with the described sequences of the two novel virus variants showed no mismatches. Their reliable detection is not affected by the described mutations."

This means laboratories can continue to reliably confirm or rule out influenza infections using R-Biopharm's RIDA®GENE (PG0505, PG0545, PG6825) assays. The tests are multiplex real-time RT-PCR for the direct qualitative detection of influenza viruses.

About R-Biopharm

 R-Biopharm AG, located in Darmstadt, is one of Germany's leading biotechnology companies. Founded in 1988, the company is family-run in the second generation and considers itself as a pioneer for health and quality of life. Its aspiration: to provide the highest possible precision, safety, clarity and certainty in prevention, therapy and healing. To this end, R-Biopharm develops technologies, products and solutions for Clinical Diagnostics, Nutrition Care and Food and Feed Analytics – and does so in internationally recognized top quality. R-Biopharm is the world market leader for test systems in the field of allergen analysis.

R-Biopharm unites research, development and sales under one roof in order to respond to ever new challenges with agile processes and to accompany the steadily growing world population into a new health era. The company is represented in more than 120 countries – through 29 subsidiaries and 120 distributors. It employs around 1,400 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the "Sustainability Award" for sustainable and profitable growth.

Press contact:

Simone Feiler
Head of Corporate Brand Communication

https://r-biopharm.com/de

https://r-biopharm.com/de/kontakt/presse

https://r-biopharm.com/de/news-presse/download-galerie

R-Biopharm AG

An der neuen Bergstraße 17

64297 Darmstadt

Phone: 0 61 51 - 81 02-538

Mobile: 0 160 - 55 273 60

Fax: 0 61 51 - 81 02-40

Email: s.feiler@r-biopharm.de

Images

Detect reliably the current flu virus variants: The RIDA®GENE flu assays from R-Biopharm
Picture: Getty Images
Detect reliably the current flu virus variants: The RIDA®GENE flu assays from R-Biopharm Picture: Getty Images
Download

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

McFIT “The Original” Launches International Franchising – One of Europe’s Most Recognized Fitness Brands Enters a New Era22.1.2026 12:00:00 CET | Press release

McFIT, a cornerstone of the European fitness landscape since 1997, is entering a new chapter in its corporate development: for the first time, the successful gym concept will be offered as an international franchise. This move paves the way for McFIT’s global franchise growth in previously untapped markets without company-owned locations.

How the CO2 price will affect heating costs in Europe22.1.2026 08:00:00 CET | Press release

The EU-wide uniform CO2 price for the building and transport sectors planned from 2028 will change the heating costs of 100 million households. A study by the Bertelsmann Stiftung shows that in many countries, including Germany, the additional burdens are likely to be limited. In Scandinavia, households could even see some relief. But in some Central and Eastern European regions, heating costs would go up noticeably. The study also shows that if the money from CO2 pricing is used the right way, it is enough to ease the burden households facing the greatest burden.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye